Connect your AI

AngioDynamics ANGO Non-cash lease expense

Other financials

Income statement

Revenue$78.4M+8.9%

Gross profit$41.5M+6.7%

Operating income-$13.0M-29.8%

Net income-$8.1M-83.4%

EPS (diluted)-$0.19-72.7%

Balance sheet

Cash & equivalents$37.8M-15.5%

Total debt$7.9M+10.2%

Total equity$173.4M-6.7%

Total assets$260.7M-8.7%

Cash flow

Operating cash flow-$3.1M+76.4%

CapEx$1.0M-43.5%

Free cash flow-$4.1M+72.4%

Valuation

Market cap$564.42M+38.7%

Enterprise value$534.51M+48.0%

P/S1.8×+0.4×

Profitability

Gross margin54.3%-0.1pp

Operating margin-11.3%-2.9pp

Net margin-10%-2.4pp

FCF margin5.5%—

Returns & leverage

Return on equity-17.5%-2.2pp

Debt / equity0×0.0×

Current ratio2.4×+0.1×

Where this comes from

Reported directly by AngioDynamics in its filing.

Tagged under the XBRL concept ango:NonCashLeaseExpense.

The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about AngioDynamics's non-cash lease expense.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AngioDynamics's non-cash lease expense?: AngioDynamics (ANGO) reported non-cash lease expense of $350K in Q4 2025.
How has AngioDynamics's non-cash lease expense changed year-over-year?: AngioDynamics's non-cash lease expense decreased by 30.4% year-over-year, from $503K to $350K.